
    
      The study is a phase II double blinded clinical trial to determine feasibility, safety and
      preliminary clinical efficacy of simvastatin to reduce leiomyoma size. Women with symptomatic
      fibroids planned to undergo surgical management for fibroids such as hysterectomy or
      myomectomy will be screened for participation. The eligible women will undergo pre-study
      evaluation to ascertain study eligibility.The study will enroll 60 participants in total,
      half will receive simvastatin and the other half will receive a placebo. The study drug and
      placebo will be an add on to the participants ongoing medical management of fibroids until
      surgery. The participants will be monitored at intervals for the effect of the drug on
      fibroid size and symptoms using ultrasound and quality of life questionnaires.
    
  